Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rupatifen fumarate
- Development stage
- Phase 3
- Lead developer
- Fujian Mindong Rejuvenation Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rupatifen fumarate is a small molecule dual antagonist of the histamine H1 receptor and the platelet-activating factor (PAF) receptor. Developed by Fujian Mindong Rejuvenation Pharmaceutical, it is currently in Phase 3 clinical development for the treatment of seasonal allergic rhinitis. The drug is designed to inhibit the inflammatory pathways associated with both the early-phase (histamine-mediated) and late-phase (PAF-mediated) allergic responses, which contribute to symptoms such as sneezing, nasal itching, and congestion. In clinical trials, it is typically administered as an oral capsule and has been evaluated in head-to-head studies against rupatadine fumarate, a structurally related antihistamine.
- Other names
- rupatifen
02
Targets
HRH1 (Histamine H1 Receptor)PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on rupatifen fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rupatifen fumarate.